Kodiak Sciences (KOD) vs Relay Therapeutics (RLAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kodiak Sciences (KOD) has outperformed Relay Therapeutics (RLAY) over the past year, gaining 540.1% versus a gain of 207.9%. Over five years, KOD leads with a -18.7% price change compared with -47.4% for RLAY. Kodiak Sciences is the larger company by market cap ($5.92 billion vs $3.82 billion), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KOD | RLAY |
|---|---|---|
| Share price | $94.26 | $17.41 |
| Market cap | $5.92B | $3.82B |
| 1-day change | +3.49% | -3.01% |
| YTD return | +225.75% | +112.17% |
| 1-year return | +540.06% | +207.89% |
| 5-year return | -18.66% | -47.38% |
| EPS (TTM) | $-4.19 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $15.36M |
| Revenue growth (YoY) | — | +53.44% |
| Net income (latest FY) | $-229.97M | $-276.48M |
| Operating margin | — | -1971.59% |
| Net margin | — | -1800.58% |
| 52-week high | $104.00 | $21.27 |
| 52-week low | $10.94 | $5.85 |
| Distance from 52-week high | -9.37% | -18.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +23.77% | +58.41% |
| Average volume | 1.56M | 2.80M |
| Shares outstanding | 62.85M | 219.14M |
| Employees | 141 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KOD has outperformed RLAY by 332.2 percentage points over the past year.
About Kodiak Sciences
KOD stock →Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
About Relay Therapeutics
RLAY stock →Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 202 employees
KOD vs RLAY FAQ
Which is bigger, Kodiak Sciences or Relay Therapeutics?
Kodiak Sciences (KOD) is larger, with a market capitalization of $5.92B compared with $3.82B for Relay Therapeutics (RLAY).
Which stock has performed better over the past year, KOD or RLAY?
KOD returned +540.06% over the past 12 months, compared with +207.89% for RLAY (price return, excluding dividends). Past performance does not predict future results.
Are Kodiak Sciences and Relay Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.